<h4>Background</h4>Treatment with androgen receptor (AR) signaling inhibitors, such as enzalutamide, can induce neural lineage plasticity in prostate cancer, potentially progressing to t-NEPC. This evidence concerns the gene AR and prostate carcinoma.